See more : ALT Telecom Public Company Limited (ALT.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Eterna Therapeutics Inc. (BTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eterna Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cheniere Energy, Inc. (LNG) Income Statement Analysis – Financial Results
- Hermès International Société en commandite par actions (RMS.PA) Income Statement Analysis – Financial Results
- China Merchants Bank Co., Ltd. (3968.HK) Income Statement Analysis – Financial Results
- Sequoia Economic Infrastructure Income Fund Limited (SEQI.L) Income Statement Analysis – Financial Results
- Galiano Gold Inc. (GAU.TO) Income Statement Analysis – Financial Results
Eterna Therapeutics Inc. (BTX)
About Eterna Therapeutics Inc.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.00K | 0.00 | 0.00 | 0.00 | 19.81M | 23.34M | 21.27M | 22.31M | 24.52M |
| Cost of Revenue | 236.00K | 497.00K | 459.00K | 98.00K | 7.84M | 8.39M | 7.09M | 8.13M | 13.06M |
| Gross Profit | -168.00K | -497.00K | -459.00K | -98.00K | 11.96M | 14.95M | 14.19M | 14.18M | 11.46M |
| Gross Profit Ratio | -247.06% | 0.00% | 0.00% | 0.00% | 60.40% | 64.07% | 66.68% | 63.55% | 46.74% |
| Research & Development | 5.92M | 10.39M | 12.71M | 3.95M | 26.00K | 72.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 14.59M | 16.84M | 14.72M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.59M | 16.84M | 14.72M | 3.30M | 13.15M | 14.41M | 15.45M | 16.46M | 18.06M |
| Other Expenses | 461.00K | -1.17M | 899.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.73M | 27.23M | 27.43M | 7.25M | 13.18M | 14.49M | 15.59M | 16.46M | 18.06M |
| Cost & Expenses | 21.20M | 27.23M | 27.43M | 7.25M | 21.02M | 22.87M | 22.68M | 24.59M | 31.12M |
| Interest Income | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Interest Expense | 614.00K | 30.00K | 74.00K | 43.00K | 249.00K | 389.00K | 498.00K | 576.00K | 484.00K |
| Depreciation & Amortization | 1.12M | 497.00K | 459.00K | 98.00K | 3.17M | 2.76M | 2.32M | 2.89M | 3.10M |
| EBITDA | -19.93M | -33.22M | -121.95M | -7.15M | 1.96M | 3.23M | 915.00K | 609.00K | -3.63M |
| EBITDA Ratio | -29,314.71% | 0.00% | 0.00% | 0.00% | 9.88% | 13.83% | 4.30% | 2.73% | -14.26% |
| Operating Income | -21.14M | -33.22M | 68.34M | -7.25M | -1.21M | 464.00K | -1.40M | -2.28M | -6.60M |
| Operating Income Ratio | -31,080.88% | 0.00% | 0.00% | 0.00% | -6.12% | 1.99% | -6.59% | -10.21% | -26.92% |
| Total Other Income/Expenses | -536.00K | 8.68M | -95.05M | -19.28M | -808.00K | -787.00K | 391.00K | -607.00K | -614.00K |
| Income Before Tax | -21.67M | -24.53M | -122.30M | -7.29M | -2.02M | -323.00K | -1.01M | -2.89M | -7.21M |
| Income Before Tax Ratio | -31,869.12% | 0.00% | 0.00% | 0.00% | -10.20% | -1.38% | -4.75% | -12.93% | -29.42% |
| Income Tax Expense | -3.00K | 45.00K | 5.00K | -19.20M | 27.00K | -64.00K | 66.00K | 38.00K | 12.00K |
| Net Income | -21.67M | -24.58M | -122.31M | 11.91M | -2.05M | -259.00K | -1.08M | -2.92M | -7.23M |
| Net Income Ratio | -31,864.71% | 0.00% | 0.00% | 0.00% | -10.34% | -1.11% | -5.06% | -13.10% | -29.47% |
| EPS | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| EPS Diluted | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| Weighted Avg Shares Out | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
| Weighted Avg Shares Out (Dil) | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index
BROOKLYN, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic...
Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer
BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic...
Brooklyn Immunotherapeutics Stock Is a Worthy Bet on Genetics Research
BTX stock holders will certainly want to brace for volatility. Still, the outlook's bullish as the company pursues its game-changing research.
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call
BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call
BTX Stock Price: 21.02% Increase Explanation
The stock price of Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) increased by 21.02% today. This is why it happened.
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing
BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
BROOKLYN, N.Y.--(BUSINESS WIRE)--Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
New CEO and Exclusive License Will Bolster Brooklyn Immunotherapeutics
Is change at the C-suite level a good thing for a company? The facts seem to indicate that it's a positive development for BTX stock holders.
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET
BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or the “Company”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today...
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Christopher Rohde, Ph.D. to the Company's Scientific Advisory Board
Source: https://incomestatements.info
Category: Stock Reports